Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions

Lilly Endowment Inc. sold a total of 180,359 shares of Eli Lilly & Co. common stock in multiple transactions on May 21, 2024, at prices ranging from $804.00 to $813.03.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., executed multiple sales of common stock on May 21, 2024.
• The transactions involved the disposal of 180,359 shares in total.
• The sales were conducted at varying prices, ranging from $804.00 to $813.03 per share.
• The sales were executed in nine separate transactions with weighted average prices reported for each.
• Following these transactions, Lilly Endowment Inc. still holds a substantial 98,712,551 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock sales, with no indication of positive or negative sentiment. It is a routine regulatory filing.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, which is common for large shareholders like Lilly Endowment Inc. It provides transparency into the trading activities of significant stakeholders in Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies, as mandated by the SEC.
• The level of detail provided, including the weighted average prices and ranges, is consistent with SEC requirements for reporting such transactions.
• The multiple transactions at varying prices are not unusual for large institutional investors managing their portfolios.

Stakeholder Impact

• The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price of Eli Lilly & Co., but the large volume of shares still held by the endowment suggests a continued long-term investment.
• The transactions provide transparency to shareholders regarding the trading activities of a major stakeholder.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, stock sale, share disposal, insider trading, common stock, shareholder